Drug Trial Radar · NCT06304103
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Mar 14, 2025
Primary completion
Dec 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Kind Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).
Conditions
- Myelodysplastic Syndromes
Interventions
AND017Drug
Administer AND017 once per day (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of HI-E/RBC-TI responding subjectsTime frame: From baseline to up to Week 25
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.